Gardasil 9

• Gardasil 9 protects against nine types of Human Papillomavirus (HPV), which can cause various cancers and genital warts.
• The vaccine is highly effective, preventing approximately 90% of HPV-related cancers and genital warts.
• Common side effects are generally mild and temporary, such as pain, swelling, or redness at the injection site.
• It is primarily recommended for individuals aged 9 to 26, with catch-up vaccination possible for those up to 45 years old.
• Dosing schedules vary based on age at the first dose.

What is Gardasil 9 and What Does it Protect Against?

Gardasil 9 is a nonavalent human papillomavirus vaccine that provides protection against nine types of HPV. Specifically, it targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. HPV types 16 and 18 are responsible for about 70% of cervical cancers and a significant percentage of other HPV-related cancers, while types 6 and 11 cause approximately 90% of genital warts. The additional five high-risk types (31, 33, 45, 52, 58) contribute to another 10-20% of cervical cancers.

The Gardasil 9 vaccine works by stimulating the body’s immune system to produce antibodies against these specific HPV types. This prepares the body to fight off future infections if exposed to the virus. By preventing infection with these high-risk HPV types, the vaccine significantly reduces the risk of developing cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers, as well as genital warts. According to the Centers for Disease Control and Prevention (CDC), HPV vaccination could prevent over 90% of HPV-attributable cancers.

Gardasil 9 Effectiveness and Common Side Effects

Gardasil 9 demonstrates high effectiveness in preventing infections and diseases caused by the HPV types it targets. Clinical trials have shown that the vaccine is nearly 100% effective in preventing cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in individuals who have not been previously exposed to these types. It is also highly effective at preventing genital warts caused by HPV types 6 and 11. The long-term protection offered by Gardasil 9 is robust, with studies indicating sustained immunity for at least 10 years, and ongoing research continues to monitor its durability.

Understanding the Gardasil 9 side effects and benefits is crucial for informed decision-making. The benefits primarily include significant protection against various HPV-related cancers and genital warts, contributing to public health by reducing the incidence of these conditions. The vaccine is generally well-tolerated, with most side effects being mild and temporary. Common side effects include:

• Pain, swelling, or redness at the injection site
• Fever
• Headache or feeling tired
• Nausea
• Muscle or joint pain

Serious allergic reactions are rare but can occur, as with any vaccine. It is recommended to remain at the vaccination clinic for about 15 minutes after receiving the vaccine to monitor for any immediate reactions. The safety profile of Gardasil 9 has been extensively studied and affirmed by health organizations worldwide, including the World Health Organization (WHO).

Who Should Get Gardasil 9? Age and Dosing

The Gardasil 9 age recommendations are established to maximize the vaccine’s effectiveness, as it works best when administered before exposure to HPV. The CDC recommends routine HPV vaccination for children aged 11 or 12 years, though it can be started as early as age 9. Vaccination at this age ensures protection before potential exposure to the virus, as the immune response is also strongest in preteens.

For individuals who did not receive the vaccine at the recommended age, catch-up vaccination is advised. It is recommended for everyone through age 26 if they were not adequately vaccinated previously. The dosing schedule varies based on the age at which the first dose is received:

• Ages 9 through 14: A two-dose series is typically administered, with the second dose given 6 to 12 months after the first.
• Ages 15 through 26: A three-dose series is recommended, with the second dose given 1 to 2 months after the first, and the third dose given 6 months after the first.

The Advisory Committee on Immunization Practices (ACIP) also recommends shared clinical decision-making regarding HPV vaccination for adults aged 27 through 45 years who were not adequately vaccinated previously. This means that individuals in this age range should discuss with their healthcare provider whether vaccination is appropriate for them, considering their individual risk factors and potential benefits. This recommendation acknowledges that while vaccination may be less effective in this age group due to prior HPV exposure, some individuals may still benefit.